Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 22285168

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2012 Mar
First author
Rosell R

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2012 Mar;13(3):216-7. doi: 10.1016/S1470-2045(12)70037-2.
    note
    Source null
    related pmid
    22285167
    relationship
    Comment in

Authors and identifiers

  1. name
    Rosell R
    type
    Author
  2. name
    Carcereny E
    type
    Author
  3. name
    Gervais R
    type
    Author
  4. name
    Vergnenegre A
    type
    Author
  5. name
    Massuti B
    type
    Author
  6. name
    Felip E
    type
    Author
  7. name
    Palmero R
    type
    Author
  8. name
    Garcia-Gomez R
    type
    Author
  9. name
    Pallares C
    type
    Author
  10. name
    Sanchez JM
    type
    Author
  11. name
    Porta R
    type
    Author
  12. name
    Cobo M
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Rosell R
    type
    Author
  2. name
    Carcereny E
    type
    Author
  3. name
    Gervais R
    type
    Author
  4. name
    Vergnenegre A
    type
    Author
  5. name
    Massuti B
    type
    Author
  6. name
    Felip E
    type
    Author
  7. name
    Palmero R
    type
    Author
  8. name
    Garcia-Gomez R
    type
    Author
  9. name
    Pallares C
    type
    Author
  10. name
    Sanchez JM
    type
    Author
  11. name
    Porta R
    type
    Author
  12. name
    Cobo M
    type
    Author
bibliography ids
  1. nci-bib-c06ec0d5182b57bba6a4d0f5
book metadata
content sha256
d86fb121a128d9372d53c04b6cb989f8ef6e9dced8572fac95795982fc300553
document type
citation
dois
  1. 10.1016/S1470-2045(11)70393-X
electronic publication date
display
2012 Jan 26
precision
day
year
2012
evidence scope
bibliographic_metadata_only
id
pubmed:22285168
immutable id
pubmed:22285168@d86fb121a128d9372d53c04b6cb989f8ef6e9dced8572fac95795982fc300553
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
3
name
The Lancet. Oncology
nlm unique id
100957246
pages
239-46
volume
13
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2012 Mar;13(3):216-7. doi: 10.1016/S1470-2045(12)70037-2.
    note
    Source null
    related pmid
    22285167
    relationship
    Comment in
outcomes validated
false
pmid
22285168
provenance
batch id
b6284687e167e7da9556
provider
NCBI PubMed ESummary
record sha256
119cf4fa43985896651fa46d71b6ce8f751077d2950ad655c5e8c62c10241103
response sha256
64d5b7bb63f574c559af2523b779a262267cbc8e8cd02a5b47f4193cc95cabd3
retrieved at
2026-09-09T23:46:45.216259+00:00
publication date
display
2012 Mar
precision
month
year
2012
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/22285168/
title
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Preserved source evidence · Not medical advice